Please note: The resources here provide general information only. The suitability of such general information varies from person to person, depending on individual circumstances. Our clinical resources are subject to copyright. The use, reproduction, distribution or adaptation of Family Planning Victoria resources is subject to our licence terms, which must be agreed to prior to use.
If you are not a clinician then you should seek specific medical or legal advice on your individual circumstances.
Statements from the Clinical Reference Group of the Medical Advisory Committee of Family Planning Alliance Australia
The Medical Advisory Committee of Family Planning Alliance Australia (FPAA) has released a collection of clinical statements on a range of contraceptive topics for health practitioners.
The FPAA Medical Advisory Committee is made up of senior medical educators, senior medical officers and medical directors of the member family planning organisations. The committee reviews current clinical practice and provides evidence and consensus-based recommendations for use by health practitioners.
The statements cover new and emerging issues in contraception and provide guidance in areas where evidence is lacking.
Etonogestrel implants (Implanon NXT®)
Combined Hormonal Contraception
Using the combined pill and vaginal ring to skip or delay bleeding is popular. Tailored pill taking involves taking the combined pill or vaginal ring (changed every 3 weeks) continuously until 4 or more days of unscheduled bleeding occurs an then having a 4 day break.
Rapid initiation of hormonal contraception decreases the efficacy of ulipristal in preventing pregnancy. If a user would like to start hormonal contraception, it will not affect the efficacy of ulipristal if it is delayed for 5 days after taking ulipristal. The efficacy of ulipristal might be decreased in current users of hormonal contraception.
If a person has a further episode of unprotected sex after taking oral emergency contraception, the dose should be repeated.